A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EZETIMIBE (ZETIA?)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 为了评估在HAART和他汀类药物治疗12周的稳定背景中加入依折麦布后直接测量的低密度脂蛋白-c的变化，与服用安慰剂12周后的低密度脂蛋白-c的变化进行比较。 目的：评价在HAART和他汀类药物治疗的稳定背景下加用依折麦布的安全性和耐受性。 次要目标： 评估依折麦布对以下心血管指标的影响： ？总胆固醇 ？非高密度脂蛋白胆固醇(非高密度脂蛋白胆固醇) 高密度脂蛋白胆固醇(高密度脂蛋白-c) 甘油三酯 高敏C反应蛋白(HsCRP) 载脂蛋白B？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: To evaluate the change in directly measured LDL-c after the addition of ezetimibe to a stable background of HAART and statin therapy for 12 weeks compared with the change in LDL-c after 12 weeks of placebo. To evaluate the safety and tolerability of ezetimibe added to a stable background of HAART and statin therapy. Secondary Objectives: Evaluate the effect of ezetimibe on the following cardiovascular measures: ¿ Total cholesterol ¿ Non-high-density lipoprotein cholesterol (non-HDL-c) ¿ High-density lipoprotein cholesterol (HDL-c) ¿ Triglycerides ¿ C- reactive protein, high sensitivity (hsCRP) ¿ Apolipoprotein B (Apo B)?????